KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Intangibles (2016 - 2019)

Arbutus Biopharma (ABUS) has disclosed Intangibles for 5 consecutive years, with $43.8 million as the latest value for Q2 2019.

  • Quarterly Intangibles fell 25.25% to $43.8 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $43.8 million through Jun 2019, down 25.25% year-over-year, with the annual reading at $43.8 million for FY2018, 25.25% down from the prior year.
  • Intangibles hit $43.8 million in Q2 2019 for Arbutus Biopharma, roughly flat from $43.8 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $390.0 million in Q2 2015 to a low of $43.8 million in Q3 2018.
  • Historically, Intangibles has averaged $165.6 million across 5 years, with a median of $99.4 million in 2016.
  • Biggest YoY gain for Intangibles was 9.5% in 2016; the steepest drop was 71.8% in 2016.
  • Year by year, Intangibles stood at $352.6 million in 2015, then crashed by 71.8% to $99.4 million in 2016, then plummeted by 41.03% to $58.6 million in 2017, then dropped by 25.25% to $43.8 million in 2018, then changed by 0.0% to $43.8 million in 2019.
  • Business Quant data shows Intangibles for ABUS at $43.8 million in Q2 2019, $43.8 million in Q1 2019, and $43.8 million in Q4 2018.